Biogen and Bio-Thera Report Results of BAT1806 (biosimilar- tocilizumab) in P-III Study for Moderate to Severe Rheumatoid Arthritis
Shots:
- The P-III study involves assesing the safety- efficacy- immunogenicity & PK of BAT1806 vs Actemra/RoActemra (tocilizumab) in 621 patients with the mod. to sev. RA with inadequate response to methotrexate
- The study met its 1EPs that demonstrated equivalent efficacy and comparable safety profile to the Actemra/RoActemra. The 1EP of the study was ACR20
- Biogen has exclusive regulatory- manufacturing- and commercial rights of BAT1806 in all countries excluding China (include Hong Kong- Macau- and Taiwan). In 2021- companies collaborated under which Bio-Thera will receive $30M payment following the achievement of P-III satisfactory results and is eligible for milestones along with royalties
Ref: Globe Newswire | Image:Biogen
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com